Exact Sciences Appoints Jeff Elliott Chief Financial Officer

Respected diagnostics industry expert will help lead efforts to capitalize on market opportunity for Cologuard

MADISON, Wis., Nov. 8, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced the appointment of Jeff Elliott as chief financial officer.  Mr. Elliott, a former senior research analyst at Robert W. Baird & Co., joined Exact Sciences as vice president, business development and strategy, in June 2016 and will begin his new role effective immediately.  

Read More

Exact Sciences' Cologuard Wins Prestigious Prix Galien Award for Best Medical Technology Product

MADISON, Wis., Oct. 28, 2016 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that Cologuard, the first and only FDA-approved noninvasive, stool DNA-based colorectal cancer screening test, has won the 2016 10th Annual Prix Galien USA Award for best medical technology product. Awarded by the Galien Foundation, the Prix Galien USA awards are among the nation's highest honors recognizing biomedical and technology product achievement associated with improving the human condition.

Read More

Exact Sciences Completes 68,000 Cologuard Tests During the Third Quarter

Revenues exceed $28 million, grow 123 percent year-over-year, 33 percent sequentially

MADISON, Wis., Oct. 26, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenues of $28.1 million during the third quarter ended Sept. 30, 2016, an increase of 123 percent from $12.6 millionin the third quarter of 2015.  The company completed approximately 68,000 Cologuard tests during the quarter, an increase of approximately 100 percent from the same quarter of 2015. Since the launch of Cologuard and through the end of the third quarter of 2016, nearly 50,000 providers have ordered the test.

Read More

Cologuard® Covered for TRICARE Beneficiaries

America's veterans, military personnel and their families provided access to non-invasive, at-home colon cancer screening option without copay

MADISON, Wis., Oct. 17, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Cologuard® is now covered under TRICARE's preventive services policies for use every three years without patient coinsurance, copayments or deductibles.  The update was made after TRICARE's review of its screening coverage policies to align them with the preventive services coverage mandate of the Affordable Care Act. TRICARE is the health care program of the U.S. Department of Defense, providing benefits to 9.4 million active-duty, reserve and National Guard personnel, veterans and their dependents.

Read More

Exact Sciences Announces Inclusion of Cologuard® in HEDIS Quality Measures

Cologuard offers opportunity for health plans, systems & providers to improve quality ratings

MADISON, Wis., Oct. 3, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Cologuard® is now included in the 2017 Healthcare Effectiveness Data and Information Set (HEDIS) quality measures for colorectal cancer screening. The new quality measures were published by the National Committee for Quality Assurance (NCQA). More than 90 percent of America's health plans measure quality based on HEDIS.

Read More

CMS Affirms Cologuard® Covered Every Three Years for Medicare Advantage Beneficiaries Without Cost Sharing

 MADISON, Wis., Aug. 15, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) announced that the Centers for Medicare and Medicaid Services (CMS) issued an updated Evidence of Coverage notice for Medicare Advantage plans that affirms such plans must include coverage of Cologuard every three years without patient coinsurance, copayments or deductibles.

Read More

Topics: Exact Sciences News

Cologuard® Coverage Expands with Updated Policies from HCSC and Florida Blue

Positive medical policies from health plans that collectively insure 18 million people

MADISON, Wis., Aug. 11, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Health Care Service Corp. (HCSC), the nation's fourth largest health insurer, and Florida Blue recently updated their medical policies to cover Cologuard. With these policy updates, 80 million people are insured by commercial plans with positive medical policies regarding Cologuard. Including Medicare, Cologuard is now covered for 62 percent of its total target population.

Read More

Topics: Exact Sciences News